Clinical trials: Gastro-intestinal Stromal Tumors
GIST - Gastrointestinal Stromal Tumor, GIST
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST.
- Conditions
- GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
- Trial name
- NCT07406633
- Testing
- KQB198, Imatinib (Gleevec)
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kumquat Biosciences Inc.
Gastro-Intestinal Stromal Tumour
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of…
- Trial name
- NCT02009423
- Testing
- Masitinib
- Volunteers
- 7 people
- Sponsor
- AB Science
Gastro-intestinal Stromal Tumours
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
- Trial name
- NCT00998751
- Testing
- oral masitinib
- Where
- France
- Volunteers
- 30 people
- Sponsor
- AB Science
Gastro Intestinal Stromal Tumor
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.
- Trial name
- NCT01506336
- Testing
- masitinib, sunitinib
- Where
- France
- Volunteers
- 44 people
- Sponsor
- AB Science